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Doxycycline has non-antibiotic effects which are necessary for lupus treatment, such as 
immunosuppressive, anti-inflammatory, and anti-depressive effects. This widely used drug 
is a promising one to be developed as lupus drug since doxycycline has no data of its 
microbial resistance and it is safe for maternity. The other benefit is that doxycycline has 
lower side effects than the current drugs for lupus treatment. It gives excellent chances for 
women with lupus to be pregnant and have healthy babies. This article contains the 
compilation data of doxycycline target sites beyond its beneficial activities for lupus and 
also its limitations. Finally, this data will be a background for doxycycline in lupus drug 
development.  
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Systemic lupus erythematosus or 
lupus is an autoummune disease that has 
many therapy problems. The drug choices 
in the guidelines for daily lupus treatments 
are limited to the unsafe off-labeled drugs 
such as cytotoxic, antimalaria, and 
corticosteroid drugs [1,2]. The side effects 
might be severe and harmful because the 
drugs are routinely used in long-term 
treatment. The cytotoxic drugs have a lot of 
side effects, such as in blood, nerves, 
gastro-intestine, and fertility. The side 
effect of anti-malarial drugs is toxic to eye 
nerves. Meanwhile, the corticosteroids 
promote so many metabolic disorders [3]. 
These data reveal the need for the safe 
drugs for lupus. 
The potential old and widely used 
drug which has beneficial effects on lupus 
is doxycycline. It has non-antibiotic effects 
which support the stability of lupus-patient 
condition. The immunosuppressive and 
anti-inflammatory [4,5] occur since it can 
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inhibit the matrix-metalloproteinase-9 as 
its target site [6–8]. This MMP-9 is crucial 
in the development of lupus severity, so it 
must be inhibited [9]. Additionally, the 
data of antidepressant effect of 
doxycycline [10,11] supports the efficacy 
to be applied in lupus treatment, because 
stresses are leading factors which make the 
lupus manifestations appear more often. 
Doxycycline does not affect the patients’ 
fertility, blood, nerves, and others [12], but 
it has some side effects in gastrointestinal 
tract [13] like others antibiotics. However, 
the side effect is mild and can be handled 
well. 
Thus, this article will briefly review 
the benefits and harms of doxycycline, 
based on its target site, if doxycycline 
applied in lupus patients. The evident-
based data of antibiotics, especially 
tetracycline derivates, in osteoarthritis and 
rheumatoid arthritis is huge support for 
developing doxycycline to be a new choice 
for lupus drug treatment.       
 
THE HISTORY OF DOXYCYCLINE 
NON-ANTIBIOTIC ACTIVITIES 
Doxycycline is a derivate of 
tetracycline, a wide spectrum antibiotic.  
Tetracycline was obtained in the 1950s 
with a single indication as antibiotic for 
acne. Then, in the next research, the 
tetracycline derivates with longer half-life 
were found in 1961 (minocycline) and 
1976 (doxycycline) [14]. Moreover, the 
other effects of this tetracycline derivates 
were obtained by time. Now, it is widely 
used for many indications, such as to treat 
rosacea, bullous dermatoses, neutrophilic 
diseases, pyoderma gangrenosum, 
sarcoidosis, aortic aneurisms, cancer 
metastasis, periodontitis, and autoimmune 
disorders rheumatoid arthritis, and 
scleroderma [15]. 
The use of antibiotics in 
autoimmune disorders is based on the 
premise that infection plays a role in 
triggering autoimmune reaction called 
“molecular mimicry,” “epitope spreading,” 
or “bystander activation.” This link could 
occur directly and indirectly [15]. Based on 
it, tetracyclines is suggested as a drug 
candidate for rheumatoid arthritis by 
scientists which expect that mycoplasma 
infection lead to rheumatoid arthritis [16]. 
The use of tetracycline, minocycline, and 
doxycycline was continued until the 
clinical study punished in the 1990s. Then, 
it was found that preliminary evidence 
indicate that doxycycline may also exert 
anti-inflammatory [17] and antioxidant 
activities. Doxycycline is more acceptable 
for therapies since minocycline indicates a 
cytotoxic side effect.   
 
DOXYCYCLINE MAIN TARGET 
SITES 
 
Doxycycline Effects on Anti-nociceptive 
and Inflammatory Cytokines 
Lupus is a systemic inflammation 
disorder with the increase of inflammation 
mediators [8,18,19]. Some experiments 
result in anti-inflammatory data of 
doxycycline. The inflammatory 
biomarkers used are IL-1β, IL-6, IL-8, and 
TNF-α. Doxycycline in the concentration 
of 2 µM significantly reduces IL-1β, IL-8, 
and TNF-α (p<0.05) expression. 
Moreover, the IL-6 can be reduced in the 
concentration of 10 µM. The results show 
the doxycycline ability to regulate the 
release of inflammation mediators by host 
cells. The subantimicrobia doses of 
doxycycline also reduce PAR2, IL-17, 
TNF-α, and mRNA expression of IL-1β 
(p<0.05) due to its MMP inhibition 
[5,20,21]. It shows that the low doses of 
doxycycline correlated to the modulation 
of pro-inflammatory genes. Doxycycline 
reveals independent effects, such as the 
inhibitions of MMPs [7,22], nitric oxide 
synthase (NOS) [4], tumor progression and 
bone resorption, angiogenesis, and 
inflammation [21]. 
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The anti-inflammation effect is 
briefly explained by Leite [4] based on the 
experiments that show that doxycycline 
can reduce the release of prostaglandins, 
proteases, lysosomes, histamine, and 
serotonin. It is also effective to reduce the 
neutrophil migration in the peritoneal 
cavity like non-steroid anti-inflammatory 
drugs. This data is supported data [19,23] 
that states doxycycline reduce the 
myeloperoxidase in human neutrophil 
significantly. The antinociceptive effect 
also present in the dose of 50 and 100 
mg/kg BW [18].  
 
Impacts on MMP-9 
Matrix metalloproteinase-9 (MMP-
9) plays an essential role in lupus and the 
level increase significantly in lupus 
patients (9,24–26), so it can be a targeted 
therapy for lupus. In this case, doxycycline 
can inhibit the MMP-9. MMPs are zinc-
dependent proteases which can degrade or 
modify the extracellular matrix 
components, including angiogenesis, 
neurogenesis, remodeling regeneration and 
synaptic plasticity, inflammatory and 
epilepsy [7]. Doxycycline affects 
specifically on MMP-9 in therapeutic 
doses [27].  
One of the lupus manifestations is 
arthritis, which known as lupus arthritis. In 
this case, it has been found that 
doxycycline inhibits osteoclastogenesis 
along with the suppression of MMP-9 
activity without affecting the expression of 
the MMP-9 protein [28]. Additionally, 
close to MMP-9, Hanemaaijer [27] also 
states based on his in vivo study that 
doxycycline down-regulates MMP-8 
(neutrophil collagenase) at both the mRNA 
and protein levels. It causes the inhibition 
of cartilage degradation at the target joints.  
In the other manifestations, such as 
lupus neural disorder, doxycycline also 
shows its benefit. It has been found that 
doxycycline could aggravate the absence-
like epileptic seizures in vivo, via MMPS 
inhibition [7]. Also, doxycycline can 
reduce a depressive-like behavior in an in 
vivo study performed by Mello [11]. The 
results show that doxycycline is 
comparable to imipramine to ameliorate 
the depressive-like behavior, reveal its 
anti-depressive activity in human.  
 





Brandt [28] reports the results of his 
double-blind trial of doxycycline at the 
dose of 100 mg twice a day in osteoarthritis 
patients. The joint space narrowing (JSN) 
in this experimental subjects were 
measured after 30 months treatment. 
Meanwhile, the severity joint pain was 
measured every 6 months. After 16 months 
treatment, the mean of JSN and joint index 
of the doxycycline group is 40% lower than 
the placebo. After 30 months treatment, it 
is only 33% lower than the placebo effect 
which is suggested as a floor effect. In 
addition, based on the follow-up, the 
progress of index knee can be inhibited by 
the use of doxycycline. This case can be a 
consideration of the use of doxycycline in 
lupus arthritis.  
 
Rheumatoid Arthritis (RA) 
Shehwaro [29] compared the 
efficacy of doxycycline in combination 
with methotrexate in early seropositive 
rheumatoid arthritis subjects. The results 
show that the combination increases the 
treatment outcome. Based on the parameter 
of American College Rheumatology 50% 
(ACR50), the low dose of doxycycline can 
increase the ACR 50 response of 
methotrexate three times higher than the 
single use of methotrexate. Moreover, the 
high dose of doxycycline can only add 
three percent higher than the low dose. 
However, the mechanism of this effect is 
not understood. It might be correlated to 
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MMPs inhibition and immunomodulatory 
activity of doxycycline.  This data is 
supported by Grimsen’s data [30], which 
states that the combination of doxycycline 
and alpha-1 antitrypsin can reduce the 
arthritis development significantly due its 
expression of IL-6, macroscopic 
appearance, and its tissue structure.   
 
Nasal polyps 
The other use of doxycycline is in 
the treatment of chronic rhinosinusitis and 
nasal polyps. Doxycycline reveals its 
moderate effect which lasted for 12 weeks. 
The duration is longer than the effect of 
methylprednisolone. Doxycycline 
significantly reduces the levels of 
myeloperoxidase and matrix 
metalloproteinase-9 in nasal secretions 
[31].     
 
CONSIDERED PROBABLE SIDE 
EFFECTS 
 
Extracellular signal-Regulated Kinases 
(ERK) defect 
Doxycycline induces ERK defect 
which results in demethylation and 
overexpression of methylation-sensitive 
genes, and then it induces lupus-like 
autoimmunity in mice [32]. This result is in 
line with the other research [33] about the 
effect of diet on the lupus manifestations 
induced by doxycycline. The use of 
doxycycline results in the presence of anti-
dsDNA, but it cannot result in lupus-like 
organ damage and disease. Obradovi [6] 
explains that doxycycline inhibits the 
capacity of IL-17 to induce MMP-9 
expression in myoblast cells by regulating 
the activation of ERK 1/2. It also protects 
C2C12 myoblast cells so that it may be 
useful for inflammatory diseases. 
However, this ambiguous data need other 





Doxycycline could be one leading 
factor of acute pancreatitis. It is based on a 
case study which [34] states that 
doxycycline might be a cause of acute 
pancreatitis, but the data cannot be 
generalized since it is only a case and the 
patient also use other drugs which had side 
effects in pancreas too. 
 
Gastrointestinal Injury 
The gastrointestinal disorder is a 
common side effect of antibiotics. 
Doxycycline leads to small vessel injury 
with fibrinoid material around the vessel in 
most patients, and a few patients had 
similar changes in the duodenum [13]. The 
information will improve patient 
awareness if they use doxycycline in long-
term treatmesnt.  
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